Alzheimer's Disease: from Detection, Disgnostics to Therapeutics

Keyphrases

1. Alzheimer's Disease 100%
2. Cyanine 75%
3. Near-infrared Imaging 45%
4. Alzheimer's Disease Model 45%
5. Early Diagnosis 44%
6. Neuroprotective Effect 41%
7. Induced Toxicity 39%
8. Magnetic Nanoparticles 37%
9. Aptamer 36%
10. Carbazole-based 34%
11. Theranostic Agent 32%
12. Amyloid Aggregation 30%
13. Blood-brain Barrier 30%
14. APPPS1 30%
15. Cognitive Improvement 30%
16. Living Cells 30%
17. Alzheimer's Disease Diagnosis 26%
18. RNA Imaging 25%
19. MicroRNA 25%
20. Early Alzheimer's Disease 25%
21. Human Serum 24%
22. Self-aggregation 22%
23. Synaptic Dysfunction 22%
24. Senile Plaques 22%
25. Amyloid Plaques 22%
26. Neuroprotective 20%
27. High Selectivity 18%
28. Ultrasensitive 18%
29. High Sensitivity 18%
30. Hybridization Chain Reaction 18%
31. Enzyme-free 18%
32. Low Abundance 18%
33. Anti-Alzheimer Drugs 17%
34. Fluorescent Probe 17%
35. Neuroprotection 17%
36. Highly Sensitive 17%
37. Intracellular Self-assembly 15%
38. Xanthohumol 15%
39. CREB Signaling Pathway 15%
40. In Vivo Labeling 15%
41. MicroRNA Imaging 15%
42. Tumor-derived Extracellular Vesicles 15%
43. Scattering Sensor 15%
44. Dual Aptamer 15%
45. Transgenic Mouse Model 15%
46. Neuropathology 15%
47. Alzheimer's Disease Brain 15%
48. Saturated Long-chain Fatty Acids 15%
49. Imaging Tools 15%
50. Contrast Agent 15%
51. Superparamagnetic Iron Oxide Nanoparticles (SPIONs) 15%
52. Acid-producing Bacteria 15%
53. Specific Probe 15%
54. NIR-II Fluorophores 15%
55. Alzheimer's Disease Detection 15%
56. Dual-modal Nanoprobe 15%
57. Dual-modal Imaging 15%
58. Brain Imaging 15%
59. Positron Emission Tomography 15%
60. Extracellular Deposits 15%
61. Low Spatial Resolution 15%
62. Imaging Magnetic Resonance 15%
63. Magnetic Resonance Imaging Contrast Agents 15%
64. Real-time Imaging 15%
65. Sandwich Structure 15%
66. High Spatial Resolution 15%
67. Attenuation 15%
68. Multifunctional Theranostics 15%
69. Polydopamine 15%
70. Dual-modal 15%
71. Magnetic Resonance Imaging 15%
72. Gold Nanoparticles 15%
73. Multiple Pathology 15%
74. Early Detection 15%
75. Nanostructures 15%
76. Messenger RNA (mRNA) 15%
77. Amyloid-β Oligomers 15%
78. Cardiac Troponin 15%
79. Non-radial 15%
80. Probe-based 15%
81. Alzheimer's Disease Biomarkers 15%
82. Sensitive Detection 15%
83. Nanoparticle-free 15%
84. Nanomaterials 15%
85. DNAzyme 15%
86. Turn-on Fluorescence 15%
87. Nanoprobe 15%
88. Toxic Oligomers 15%
89. Cardiac Biomarkers 15%
90. Binding Affinity 15%
91. Mouse Model 15%
92. Target-triggered 15%
93. Surface-enhanced Raman Scattering 15%
94. Nucleic Acids 15%
95. Direct Detection 15%
96. Fluorescence Imaging 15%
97. Nanosystems 15%
98. Immunomagnetic 15%
99. Fluorometric Assay 15%
100. Ligase 15%
101. Thrombin 15%
102. Inhibitory Effect 15%
103. CaMKII 15%
104. Therapeutic Treatment 15%
105. Disease Progression 15%
106. DNA Nanodevice 15%
107. Theranostics 15%
108. Imaging Probe 15%
109. Colonic Motility 15%
110. Fluoro 15%
111. Circulating microRNA 15%
112. Ca2+ 15%
113. Blood-brain Barrier Permeability 13%
114. Biocompatibility 12%
115. Near-infrared 11%
116. Oligomeric 11%
117. Fluorescence Enhancement 11%
118. In Vivo Imaging 11%
119. Early Intervention 11%
120. Therapeutic Potential 10%
121. YOYO-1 9%
122. Fluorescent Indicator 9%
123. Limit of Detection 9%
124. Neonatal Maternal Separation 9%
125. Functionalized Magnetic Nanoparticles 9%
126. Oligomerization 8%
127. Phosphorylated tau 8%
128. Imaging in Vivo 7%
129. Progression Monitoring 7%
130. Binding Potential 7%
131. Near-infrared Fluorescent Probe 7%
132. Soluble Oligomers 7%
133. Low Biotoxicity 7%
134. In Vitro Labeling 7%
135. Fluorescent Molecules 7%
136. Plaque Imaging 7%
137. Self-forming 7%
138. Barrier Penetrability 7%
139. Early Therapy 7%
140. MicroRNA-149 7%
141. ROS Production 7%
142. Design Strategy 7%
143. Autofluorescence 7%
144. Dementia 7%
145. Non-invasive Method 7%
146. Double Transgenic 7%
147. Ca2+ Influx 7%
148. Molecular Beacon 7%
149. Lipophilic 7%
150. Detection Assay 7%
151. Synergistic Effect 7%
152. Biological Products 7%
153. Charged Molecules 7%
154. Novel Therapies 7%
155. Double Transgenic Mice 7%
156. Trace Amount 7%
157. Binding Ability 7%
158. Strong Fluorescence 7%
159. Weak Binding 7%
160. Systemic Administration 7%
161. Plaque 7%
162. Optical Characteristics 7%
163. Neurodegenerative 7%
164. Aggregation Inhibitor 7%
165. Penetration Depth 7%
166. Effectiveness Evaluation 7%
167. Alkyl Chain 7%
168. Main Components 7%
169. Amyloid-β Peptide 7%
170. High Specificity 6%
171. Aptamer-based 6%
172. Total Internal Reflection Fluorescence Microscopy 6%
173. Transgenic 6%
174. Biological Properties 6%
175. In Vivo Efficacy 6%
176. Disease Diagnosis 6%
177. Triple Transgenic 6%
178. Hairpin Probe 6%
179. Capture DNA 6%
180. Myocardial Infraction 6%
181. Dual Signal Amplification 6%
182. Detection Device 6%
183. Reaction Products 6%
184. Hairpin 6%
185. Gastrointestinal Motility Disorder 5%
186. Gastrointestinal Motility 5%
187. Tau Levels 5%
188. Sensitive Sensor 5%
189. Enhanced Raman 5%
190. Simple Sensor 5%
191. Days of Treatment 5%
192. Pathological Characteristics 5%
193. Raman Signal 5%
194. Primary Neurons 5%
195. Cyanine Fluorophores 5%
196. Therapeutic Target 5%
197. Fibrillation 5%
198. Intraperitoneal Injection 5%
199. Diluted Human Serum 5%
200. Hyperphosphorylation 5%